← Back to Search

CAR T-cell Therapy

CTX120 for Multiple Myeloma

Phase 1

Waitlist Available

Research Sponsored by CRISPR Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years

Eastern Cooperative Oncology Group performance status 0 or 1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from ctx120 infusion up to 60 months post-infusion

Awards & highlights

Study Summary

This trial is testing a new drug for safety and effectiveness in patients who have multiple myeloma that has returned after treatment or is resistant to treatment.

Who is the study for?

This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment after at least two prior therapies. They must be fairly active and healthy, with good organ function, and willing to use birth control for a year post-treatment. People can't join if they've had certain other treatments like gene therapy, have heart issues or infections like HIV, are pregnant/breastfeeding, or have serious mental health conditions.Check my eligibility

What is being tested?

The study is testing CTX120's safety and effectiveness in treating relapsed or refractory multiple myeloma. It's an early-phase (Phase 1), single-arm trial where all participants receive the same experimental therapy without a comparison group.See study design

What are the potential side effects?

While specific side effects of CTX120 aren't listed here, similar treatments often cause immune reactions, fatigue, fever, nausea; there may also be risks related to cell infusions such as shortness of breath or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am fully active or can carry out light work.

Select...

My multiple myeloma has returned or didn't respond to treatment, and I've had at least 2 prior treatments.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

I am 18 years old or older.

Select...

My multiple myeloma has returned or didn't respond after 2 treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from ctx120 infusion up to 60 months post-infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from ctx120 infusion up to 60 months post-infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx120 infusion up to 60 months post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part A (dose escalation): Incidence of adverse events

Part B (cohort expansion): Objective response rate

Secondary outcome measures

Overall Survival

Progression Free Survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: CTX120Experimental Treatment1 Intervention

Administered by IV infusion following lymphodepleting chemotherapy.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor

8 Previous Clinical Trials

866 Total Patients Enrolled

Annie Weaver, PhDStudy DirectorCRISPR Therapeutics

2 Previous Clinical Trials

347 Total Patients Enrolled

Ewelina Morawa, MDStudy DirectorCRISPR Therapeutics

1 Previous Clinical Trials

227 Total Patients Enrolled

Media Library

CTX120 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04244656 — Phase 1

Multiple Myeloma Research Study Groups: CTX120

Multiple Myeloma Clinical Trial 2023: CTX120 Highlights & Side Effects. Trial Name: NCT04244656 — Phase 1

CTX120 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04244656 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial have any open slots for enrollees at the moment?

"The clinicaltrials.gov listing for this medical trial reveals that it is not presently looking to include new candidates, despite having been initially posted on 1/22/2020 and lastly updated on 7/14/2022. Nonetheless, 807 other trials are currently accepting patients at this time."

Answered by AI

How many North American locations are currently conducting this clinical trial?

"As of now, this medical study is accepting patients at 5 select sites. These include the cities of Philadelphia, Chicago and Nashville as well as two other locations. To reduce travel needs, it would be beneficial to register with a clinic located in close proximity."

Answered by AI

Has CTX120 been granted official acceptance by the FDA?

"Our research team has concluded that CTX120 is likely safe, awarding it a score of 1. This assessment was made due to the Phase 1 trial status and limited evidence for efficacy or safety."

Answered by AI